DUPIXENT (dupilumab)
ECZEMA AGENTS SYSTEMIC INTERLEUKIN-4 (IL-4RA)ANTAG.MCAB·ATOPIC DERMATITIS·+10
Sanofi-Aventis U.S.
Indication
Eosinophilic esophagitis
Eosinophilic esophagitis is a chronic, immune- and antigen-mediated inflammatory disorder affecting the gastrointestinal tract, specifically the esophagus. Read more about Eosinophilic esophagitis
4 drugs 2 manufacturers
Drugs that treat it
Common Eosinophilic esophagitis therapies.
DUPIXENT PEN (dupilumab)
ECZEMA AGENTS SYSTEMIC INTERLEUKIN-4 (IL-4RA)ANTAG.MCAB·ATOPIC DERMATITIS·+10
Sanofi-Aventis U.S.
DUPIXENT SYRINGE (dupilumab)
ECZEMA AGENTS SYSTEMIC INTERLEUKIN-4 (IL-4RA)ANTAG.MCAB·ATOPIC DERMATITIS·+10
Sanofi-Aventis U.S.
EOHILIA (budesonide)
GLUCOCORTICOSTEROIDS·EOSINOPHILIC ESOPHAGITIS
Takeda Pharmaceuticals America
Filter & compare in the drug finder →Opens the drug finder with Eosinophilic esophagitis preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonEosinophilic esophagitis is a chronic, immune- and antigen-mediated inflammatory disorder affecting the gastrointestinal tract, specifically the esophagus.
It can occur in both pediatric and adult populations, frequently in individuals with concurrent atopic conditions.
Pathophysiologically, localized type 2 helper T-cell inflammation triggered by food or aeroallergens drives epithelial barrier disruption and dense eosinophilic infiltration of the esophageal mucosa.
Over time, persistent inflammation leads to tissue remodeling and progressive esophageal dysfunction, commonly presenting as dysphagia, chest pain, and food impaction in adults, or feeding refusal, vomiting, and failure to thrive in young children.
- nih.gov
Eosinophilic esophagitis is a chronic, immune- and antigen-mediated inflammatory disorder affecting the gastrointestinal tract, specifically the esophagus
- nih.gov
Eosinophilic esophagitis is a chronic, immune- and antigen-mediated inflammatory disorder affecting the gastrointestinal tract, specifically the esophagus It can occur in both pediatric and adult populations, frequently in individuals with concurrent atopic conditions Pathophysiologically, localized type 2 helper T-cell inflammation triggered by food or aeroallergens drives epithelial barrier disruption and dense eosinophilic infiltration of the esophageal mucosa
- nih.gov
Pathophysiologically, localized type 2 helper T-cell inflammation triggered by food or aeroallergens drives epithelial barrier disruption and dense eosinophilic infiltration of the esophageal mucosa
- nih.gov
Over time, persistent inflammation leads to tissue remodeling and progressive esophageal dysfunction, commonly presenting as dysphagia, chest pain, and food impaction in adults, or feeding refusal, vomiting, and failure to thrive in young children
- mayoclinic.org
Over time, persistent inflammation leads to tissue remodeling and progressive esophageal dysfunction, commonly presenting as dysphagia, chest pain, and food impaction in adults, or feeding refusal, vomiting, and failure to thrive in young children
Personalize your experience
Follow Eosinophilic esophagitis and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.